PURPOSE: Immunogenicity is a major reason for secondary loss of response to infliximab (IFX). Recent work suggested potentially lower immunogenicity of subcutaneous (SC) compared to intravenous (IV) IFX. However, it is unknown whether re-exposure to IFX SC after secondary loss of response and immunogenicity to its intravenous formulation is safe and effective. METHODS: In a retrospective cohort study conducted at two medical centers, patients with clinically (Harvey-Bradshaw Index ≥ 5) and/or biochemically (fecal calprotectin > 250 µg/g) active Crohn's disease (CD) and previous immunogenic failure of IFX IV underwent exposure to IFX SC. Harvey-Bradshaw Index, fecal calprotectin, IFX serum concentration, and anti-drug antibodies were assessed until month 12. RESULTS: Twenty CD patients were included. The majority of patients (90%) had previous treatment with three or more biologics. Fifteen (75%) and ten (50%) of 20 patients continued IFX SC treatment until months 6 and 12, respectively. No immediate hypersensitivity reactions were observed. Two patients discontinued IFX SC treatment because of delayed hypersensitivity at week 2 and week 4. IFX serum concentrations increased from baseline to month 12, while anti-drug antibody levels decreased. Combined clinical and biochemical remission at month 12 was observed in seven of 20 patients (35%). CONCLUSION: Subcutaneous infliximab treatment of Crohn's disease patients with previous immunogenic failure of intravenous infliximab was well tolerated and effective in a cohort of patients with refractory Crohn's disease.

Center for Regenerative Therapies Dresden Dresden Germany

Clinical and Research Center for Inflammatory Bowel Disease ISCARE and 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Internal Medicine A University Medicine Greifswald Greifswald Germany

Department of Medicine 1 University Hospital Carl Gustav Carus Dresden Technische Universität Fetscherstrasse 74 01307 Dresden Germany

Zobrazit více v PubMed

Lichtenstein GR, Loftus EV, Isaacs KL et al (2018) ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 113:481–517. 10.1038/ajg.2018.27 PubMed

Torres J, Bonovas S, Doherty G et al (2020) ECCO Guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohn’s Colitis 14:4–22. 10.1093/ecco-jcc/jjz180 PubMed

Rubin DT, Ananthakrishnan AN, Siegel CA et al (2019) ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 114:384–413. 10.14309/ajg.0000000000000152 PubMed

Harbord M, Eliakim R, Bettenworth D et al (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management. J Crohns Colitis 11:769–784. 10.1093/ecco-jcc/jjx009 PubMed

Kennedy NA, Heap GA, Green HD et al (2019) Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 4:341–353. 10.1016/S2468-1253(19)30012-3 PubMed

Nanda KS, Cheifetz AS, Moss AC (2013) Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 108:40–7. 10.1038/ajg.2012.363. quiz 48 PubMed PMC

VandeCasteele N, Khanna R, Levesque BG et al (2015) The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut 64:1539–1545. 10.1136/gutjnl-2014-307883 PubMed PMC

Melsheimer R, Geldhof A, Apaolaza I, Schaible T (2019) Remicade(®) (infliximab): 20 years of contributions to science and medicine. Biologics 13:139–178. 10.2147/BTT.S207246 PubMed PMC

Rutgeerts P, Feagan BG, Lichtenstein GR et al (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:402–413. 10.1053/j.gastro.2003.11.014 PubMed

Brun MK, Goll GL, Jørgensen KK et al (2022) Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial. J Intern Med 292:477–491. 10.1111/joim.13495 PubMed PMC

Atiqi S, Hooijberg F, Loeff FC et al (2020) Immunogenicity of TNF-inhibitors. Front Immunol 11:312. 10.3389/fimmu.2020.00312 PubMed PMC

Sazonovs A, Kennedy NA, Moutsianas L et al (2020) HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology 158:189–199. 10.1053/j.gastro.2019.09.041 PubMed

Viola M, Sequeira J, Seiça R et al (2018) Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control release Off J Control Release Soc 286:301–314. 10.1016/j.jconrel.2018.08.001 PubMed

Hamuro L, Kijanka G, Kinderman F et al (2017) Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. J Pharm Sci 106:2946–2954. 10.1016/j.xphs.2017.05.030 PubMed

Kim H, Alten R, Cummings F et al (2021) Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs 13:1868078. 10.1080/19420862.2020.1868078 PubMed PMC

Schreiber S, Ben-Horin S, Leszczyszyn J et al (2021) Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology 160:2340–2353. 10.1053/J.GASTRO.2021.02.068 PubMed

Westhovens R, Wiland P, Zawadzki M et al (2021) Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology (Oxford) 60:2277–2287. 10.1093/rheumatology/keaa580 PubMed PMC

Yoo D-H, Westhovens R, Ben-Horin S, et al (2018) Development of a subcutaneous formulation of CT-P13 (infliximab): maintenance subcutaneous administration may elicit lower immunogenicity compared to intravenous treatment. Arthritis Rheumatol 70

Ben-Horin S, Reinisch W, Duk Ye B (2018) Development of a subcutaneous formulation of ct-p13 [infliximab]: maintenance subcutaneous administration may elicit lower immunogenicity compared with intravenous treatment. United Eur Gastroenterol J 6

Schreiber S, Ben-Horin S, Alten R et al (2022) Perspectives on subcutaneous infliximab for rheumatic diseases and inflammatory bowel disease: before, during, and after the COVID-19 Era. Adv Ther 39:2342–2364. 10.1007/s12325-021-01990-6 PubMed PMC

Caron B, Fumery M, Netter P, Peyrin-Biroulet L (2022) Letter: treatment with subcutaneous CT-P13 in Crohn’s disease patients with intravenous infliximab failure. Aliment Pharmacol Ther 55:508–509. 10.1111/apt.16770 PubMed

Cerna K, Duricova D, Lukas M et al (2023) Subcutaneous infliximab in refractory Crohn’s disease patients: a possible biobetter? Crohn’s Colitis 360(5):otad040. 10.1093/crocol/otad040 PubMed PMC

Roblin X, Veyrard P, Bastide L et al (2022) Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn’s disease. Aliment Pharmacol Ther 56:77–83. 10.1111/apt.16852 PubMed

O’Meara S, Nanda KS, Moss AC (2014) Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 20:1–6. 10.1097/01.MIB.0000436951.80898.6d PubMed

Smith PJ, Critchley L, Storey D et al (2022) Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study. J Crohns Colitis 16:1436–1446. 10.1093/ecco-jcc/jjac053 PubMed PMC

Iannone F, Conti F, Cauli A et al (2022) Subcutaneously-administered infliximab in the management of rheumatoid arthritis: a short narrative review of current clinical evidence. J Inflamm Res 15:3259–3267. 10.2147/JIR.S240593 PubMed PMC